Carbidopa, Levodopa and Entacapone Tablets
Dosage form: tablet, film coated
Drug class:Dopaminergic antiparkinsonism agents
Medically reviewed by Drugs.com. Last updated on Feb 1, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
INDICATIONS AND USAGE
Carbidopa, Levodopa and Entacapone Tablets, are indicated for the treatment of Parkinson’s disease.
Carbidopa, Levodopa and Entacapone Tablets can be used:
- To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products.
- To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias.
DOSAGE AND ADMINISTRATION
Carbidopa, Levodopa and Entacapone Tablets should be used as a substitute for patients already stabilized on equivalent doses of carbidopa/levodopa and entacapone. However, some patients who have been stabilized on a given dose of carbidopa/levodopa may be treated with Carbidopa, Levodopa and Entacapone Tablets if a decision has been made to add entacapone (see below). Therapy should be individualized and adjusted according to the desired therapeutic response.
Dosing Information
The optimum daily dosage of Carbidopa, Levodopa and Entacapone Tablets must be determined by careful titration in each patient.
Clinical experience with daily doses above 1,600 mg of entacapone is limited. The maximum recommended daily dose of Carbidopa, Levodopa and Entacapone Tablets depends on the strength used. The maximum number of tablets to be used in a 24-hour period is less with the highest strength (Carbidopa, Levodopa and Entacapone Tablets 50 mg/200 mg/200 mg) than with lower strengths (see Table 1). Studies show that peripheral dopa decarboxylase is saturated by carbidopa at approximately 70 mg per day to 100 mg per day. Patients receiving less than this amount of carbidopa are more likely to experience nausea and vomiting.
